Aurobindo Pharma Foundation Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 17-12-2024
- Paid Up Capital ₹ 0.10 M
as on 17-12-2024
- Company Age 4 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 39.88%
(FY 2023)
- Profit -100.00%
(FY 2023)
- Ebitda -520.00%
(FY 2023)
- Net Worth
- Total Assets -46.24%
(FY 2023)
About Aurobindo Pharma Foundation
The Company is engaged in the Veterinary Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Nityananda Kambam, Sivakumaran Meenakshisunderam, and Sarath Penaka serve as directors at the Company.
- CIN/LLPIN
U85200TG2020NPL141954
- Company No.
141954
- Company Classification
Private Not For Profit Company
- Incorporation Date
20 Jul 2020
- Date of AGM
28 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Aurobindo Pharma Foundation?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nityananda Kambam  | Director | 20-Jul-2020 | Current |
| Sivakumaran Meenakshisunderam | Director | 20-Jul-2020 | Current |
| Sarath Penaka | Director | 20-Jul-2020 | Current |
Financial Performance and Corporate Structure Insights of Aurobindo Pharma Foundation.
Aurobindo Pharma Foundation, for the financial year ended 2023, experienced significant growth in revenue, with a 39.88% increase. The company also saw a substantial fall in profitability, with a 100% decrease in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth | |||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aurobindo Pharma Foundation?
In 2023, Aurobindo Pharma Foundation had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Apl Healthcare LimitedActive 18 years 1 day
Nityananda Kambam and Sivakumaran Meenakshisunderam are mutual person
- Curateq Biologics Private LimitedActive 4 years 7 months
Sivakumaran Meenakshisunderam is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aurobindo Pharma Foundation?
Aurobindo Pharma Foundation has a workforce of 18 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aurobindo Pharma Foundation, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aurobindo Pharma Foundation's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
